The demand for checkpoint inhibitors, especially those targeting PD-1 and PD-L1, has risen significantly in the past couple of years. Cancer therapies that target either PD-1 or PD-L1 can stop them from attaching and prevent cancer cells from hiding.
https://finance.yahoo.com/news/mercks-cancer-immunotherapy-keytruda-continues-114811173.html